Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
PAAA vs PHLAX
Shared holdings
1
PAAA covered by PHLAX
5.19%
PHLAX covered by PAAA
5.19%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
PAAA (Feb. 27, 2026)
| Security | Weight | |
|---|---|---|
| (PIPA070) PGIM Core Government Money Market Fund | 5.19% | |
| Carlyle US CLO Ltd., Series 2023-3A, Class A1R | 1.00% | |
| SYMP 2021-28A AR | 1.00% | |
| Golub Capital Partners CLO 37B Ltd | 1.00% | |
| Balboa Bay Loan Funding 2022-1 Ltd | 0.99% | |
| Madison Park Funding XXXIV Ltd | 0.99% | |
| 720 East CLO VII Ltd., Series 2025-7A, Class A1 | 0.93% | |
| BABSN 2025-7A A1 | 0.93% | |
| RR 26 Ltd | 0.92% | |
| GARNET CLO 3 LTD SER 2025-3A CL A1 V/R REGD 144A P/P 5.19042000 | 0.86% | |
| Elmwood CLO 41 Ltd., Series 2025-4A, Class A | 0.86% | |
| Park Blue CLO 2023-IV Ltd | 0.86% | |
| CIFC Funding 2025-III Ltd., Series 2025-3A, Class A1 | 0.83% | |
| Ballyrock Clo 32 Ltd | 0.82% | |
| RR 27 Ltd., Series 2023-27A, Class A1AR | 0.80% | |
| Signal Peak CLO 14 Ltd., Series 2024-14A, Class A | 0.77% | |
| Madison Park Funding LX Ltd | 0.74% | |
| Empower CLO Ltd., Series 2025-1A, Class A | 0.73% | |
| MDPK 2025-40RA A | 0.72% | |
| Golub Capital Partners CLO 69M | 0.70% | |
| Empower CLO Ltd., Series 2023-2A, Class AR | 0.70% | |
| Magnetite Xlii Ltd | 0.68% | |
| CGMS 2017-3A A1R2 10/37 | 0.67% | |
| Balboa Bay Loan Funding Ltd., Series 2020-1A, Class A1RR | 0.67% | |
| OHA Credit Funding 3 Ltd., Series 2019-3A, Class AR2 | 0.67% | |
| KKR FINANCIAL CLO LTD KKR 40A AR 144A | 0.66% | |
| Madison Park Funding XLVIII Ltd., Series 2021-48A, Class AR | 0.66% | |
| Bain Capital Credit CLO 2022-5 Ltd | 0.66% | |
| WOODS 2020-22A A1R3 | 0.66% | |
| Neuberger Berman Loan Advisers CLO Ltd., Series 2022-51A, Class AR | 0.66% | |
| Barings CLO Ltd 2025-III | 0.66% | |
| OHA Credit Funding 5 Ltd., Series 2020-5A, Class AR | 0.65% | |
| Neuberger Berman Loan Advisers CLO Ltd., Series 2019-33A, Class AR2 | 0.64% | |
| ARES XLIV CLO Ltd. Floating Rate, Due 04/15/2034 | 0.64% | |
| AGL Core CLO 15 Ltd | 0.64% | |
| HPS LOAN MANAGEMENT 2021-16 LTD HLM 2021-16A A1R | 0.64% | |
| CARVL 2022-2A A1R | 0.63% | |
| CarVal CLO VI-C Ltd | 0.62% | |
| CarVal CLO VII-C Ltd., Series 2023-1A, Class A1R | 0.62% | |
| LCM 40 Ltd., Series 40A, Class A1R | 0.61% | |
| BALBOA BAY LOAN FUNDING LTD 2023-1A ARR TSFR3M+116 04/20/2036 144A | 0.61% | |
| Madison Park Funding LVII Ltd., Series 2022-57A, Class A1R | 0.61% | |
| Kennedy Lewis CLO 23, Ltd., Series 2025-23A, Class A | 0.60% | |
| Regatta Funding Ltd., Series 2025-4A, Class A1 | 0.60% | |
| OCTAGON 64 LTD OCT64 2022 1A A1R 144A | 0.60% | |
| CIFC Funding Ltd., Series 2021-4A, Class AR | 0.60% | |
| Elmwood CLO II Ltd., Series 2019-2A, Class A1RR | 0.60% | |
| New Mountain CLO 3 Ltd., Series CLO-3A, Class A1R | 0.60% | |
| Menlo CLO Ltd., Series 2024-1A, Class A1 | 0.59% | |
| Kennedy Lewis CLO 19 Ltd., Series 2025-19A, Class A | 0.59% |
PHLAX (Feb. 27, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 16.46% | |
| (PIPA070) PGIM Core Government Money Market Fund | 7.57% | |
| MERCK & CO | 5.90% | |
| GILEAD SCIENCES INC | 4.29% | |
| UNITEDHEALTH GRP | 4.23% | |
| VERTEX PHARMACEUTICALS INC | 3.49% | |
| CVS HEALTH CORP | 3.21% | |
| LONZA GROUP -REG | 3.07% | |
| ARGENX SE SPONSORED ADR | 3.05% | |
| REGENERON PHARMACEUTICALS INC | 3.01% | |
| DANAHER CORP | 2.99% | |
| THERMO FISHER SCIENTIFIC INC | 2.74% | |
| ROIVANT SCIENCES LTD | 1.99% | |
| VAXCYTE INC | 1.92% | |
| TEVA PHARMACEUTICAL IND ADR | 1.90% | |
| BEONE MEDICINES LTD ADR | 1.87% | |
| PALVELLA THERAPEUTICS INC | 1.66% | |
| AGILENT TECHNOLOGIES INC | 1.66% | |
| SIONNA THERAPEUTICS INC | 1.60% | |
| SCHOLAR ROCK HOLDING CORP | 1.56% | |
| PRUDENTIAL INVESTMENT PORTFOLIOS 2 PRUDENTIAL INSTITUTIONA 0.00000000 | 1.55% | |
| EDWARDS LIFESCIENCES CORP | 1.53% | |
| XENON PHARMACEUTICALS INC | 1.52% | |
| INSMED INC | 1.34% | |
| KYMERA THERAPEUTICS INC | 1.33% | |
| NEWAMSTERDAM PHARMA COMPANY NV | 1.27% | |
| APOGEE THERAPEUTICS INC | 1.13% | |
| ASTRAZENECA PLC | 1.11% | |
| Bayer Aktiengesellschaft | 1.02% | |
| CRINETICS PHARMACEUTICALS INC | 0.99% | |
| VIRIDIAN THERAPEUTICS INC | 0.91% | |
| DISC MEDICINE INC | 0.89% | |
| TANDEM DIABETES CARE INC | 0.84% | |
| APELLIS PHARMACEUTICALS INC | 0.84% | |
| PROTAGONIST THERAPEUTICS INC | 0.84% | |
| TARSUS PHARMACEUTICALS INC | 0.83% | |
| MINERALYS THERAPEUTICS INC | 0.79% | |
| CABALETTA BIO INC | 0.79% | |
| ALIGN TECHNOLOGY INC | 0.78% | |
| UCB SA | 0.74% | |
| ARCUTIS BIOTHERAPEUTICS INC | 0.71% | |
| REVOLUTION MEDICINES INC | 0.66% | |
| OLEMA PHARMACEUTICALS INC | 0.56% | |
| CELCUITY INC | 0.55% | |
| IMMUNOVANT INC | 0.52% | |
| TYRA BIOSCIENCES INC | 0.41% | |
| LB PHARMACEUTICALS INC | 0.37% | |
| Abivax SA SPONSORED ADS | 0.37% | |
| COMPASS Pathways PLC, ADR | 0.28% | |
| UNIQURE N.V. | 0.24% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.